HDAC4 reduction: a novel therapeutic strategy to target cytoplasmic huntingtin and ameliorate neurodegeneration - Wikidata - awgldk - TriplyDB

HDAC4 reduction: a novel therapeutic strategy to target cytoplasmic huntingtin and ameliorate neurodegeneration

HDAC4 reduction: a novel therapeutic strategy to target cytoplasmic huntingtin and ameliorate neurodegeneration

http://www.wikidata.org/entity/Q27316520

about

Sharing big biomedical data HDAC signaling in neuronal development and axon regeneration Possible protective action of neurotrophic factors and natural compounds against common neurodegenerative diseases Reinstating aberrant mTORC1 activity in Huntington's disease mice improves disease phenotypes.HDAC4-myogenin axis as an important marker of HD-related skeletal muscle atrophy Aberrant Expression of Histone Deacetylases 4 in Cognitive Disorders: Molecular Mechanisms and a Potential Target Regulation of class IIa HDAC activities: it is not only matter of subcellular localization Histone Deacetylase (HDAC) Inhibitors - emerging roles in neuronal memory, learning, synaptic plasticity and neural regeneration Epigenetics and therapeutic targets mediating neuroprotection The promise and perils of HDAC inhibitors in neurodegeneration Post-translational modifications regulate class IIa histone deacetylase (HDAC) function in health and disease HDAC4 does not act as a protein deacetylase in the postnatal murine brain in vivo Epigenetic changes as a common trigger of muscle weakness in congenital myopathies.Protein kinase D1 mediates class IIa histone deacetylase phosphorylation and nuclear extrusion in intestinal epithelial cells: role in mitogenic signaling Early transcriptional alteration of histone deacetylases in a murine model of doxorubicin-induced cardiomyopathy.The Huntington's disease-related cardiomyopathy prevents a hypertrophic response in the R6/2 mouse model.Skeletal muscle pathology in Huntington's disease Targets for future clinical trials in Huntington's disease: what's in the pipeline?Regulation of neuronal gene expression and survival by basal NMDA receptor activity: a role for histone deacetylase 4.Huntington's disease accelerates epigenetic aging of human brain and disrupts DNA methylation levels.Transcription, epigenetics and ameliorative strategies in Huntington's Disease: a genome-wide perspective Disruption of the nuclear membrane by perinuclear inclusions of mutant huntingtin causes cell-cycle re-entry and striatal cell death in mouse and cell models of Huntington's disease.Differential effect of HDAC3 on cytoplasmic and nuclear huntingtin aggregates.Integration-independent Transgenic Huntington Disease Fragment Mouse Models Reveal Distinct Phenotypes and Life Span in Vivo.Blocking the association of HDAC4 with MAP1S accelerates autophagy clearance of mutant Huntingtin.Quantitative Electroencephalographic Analysis Provides an Early-Stage Indicator of Disease Onset and Progression in the zQ175 Knock-In Mouse Model of Huntington's Disease.Deimmunization for gene therapy: host matching of synthetic zinc finger constructs enables long-term mutant Huntingtin repression in mice.LBH589, A Hydroxamic Acid-Derived HDAC Inhibitor, is Neuroprotective in Mouse Models of Huntington's Disease.Transcriptional Signature of an Altered Purine Metabolism in the Skeletal Muscle of a Huntington's Disease Mouse Model Involvement of HDAC1 and HDAC3 in the Pathology of Polyglutamine Disorders: Therapeutic Implications for Selective HDAC1/HDAC3 Inhibitors.Class IIa HDACs - new insights into their functions in physiology and pathology.The role of dietary histone deacetylases (HDACs) inhibitors in health and disease.Panobinostat: a review of trial results and future prospects in multiple myeloma.HDAC4 as a potential therapeutic target in neurodegenerative diseases: a summary of recent achievements Chromatin Changes Associated with Neuronal Maintenance and Their Pharmacological Application.Unravelling and Exploiting Astrocyte Dysfunction in Huntington's Disease.Targeting ATM ameliorates mutant Huntingtin toxicity in cell and animal models of Huntington's disease.Huntington's Disease: Mechanisms of Pathogenesis and Therapeutic Strategies.Transcriptome analysis of genes and gene networks involved in aggressive behavior in mouse and zebrafish.Human Sirtuin 2 Localization, Transient Interactions, and Impact on the Proteome Point to Its Role in Intracellular Trafficking.

P2860

Q21146606-48B8CBD7-DA84-4773-BC1A-34A4F5221ED7 Q27013969-642ABCDD-E72C-40E0-BF26-223F73293B9C Q27024349-4A8EA40C-D3EA-4968-9A96-E9624395DC30 Q27306293-4641FED0-3802-497E-ACE5-46E38A3F836B Q27311425-8AE6B865-6D69-417F-AC1E-8B50047E8BD6 Q28066685-B8857E7C-F21E-49E2-8041-68765E6632A6 Q28077331-3FB33209-4CBF-4D0F-B1B1-46EC36C383D7 Q28080593-F127C77D-863E-4C24-8844-B4EA8E5C7403 Q28080633-9D6DEA96-507A-477D-AFA2-7E6386022340 Q28087539-4FFEB051-6366-41F5-A2D7-DCB25021D35B Q28088517-CF363CD2-6DEE-408F-B959-55C62589151B Q28535389-86B151D9-81D6-4254-B54F-B5A534DE2143 Q29977760-70BE96CF-3FB3-418B-9A50-76652C1DDD4B Q33626512-D8AA06D5-7F74-4D84-97C7-9105EC4DE54F Q33853732-3C78EA57-D3AF-4737-928E-444E89E0DFD5 Q34277801-D40F8B96-0E8B-4B41-9252-AC8D2BF4582C Q34292092-4482AEDF-612F-4545-AEC4-8D00F56B2E40 Q34435001-221A5B0A-5EA3-4442-B4ED-971CD2FC6DFA Q34491694-5EFB6239-AC7B-4D12-9CE7-60233F61B23F Q34535959-416C5E5E-F49B-48E9-8FC1-1C267F95DA7C Q35024695-357EB24C-5E66-4460-B1C2-FBA676FED2D4 Q35239346-5CBEB447-2F1E-4460-A772-98D722637571 Q35403365-4FD9949C-7095-4945-B476-9398A6387BC6 Q35905407-11D9CD3F-EAEE-4C2B-A083-3BFAE018F12D Q36260249-73E9B518-5DA4-4DAA-A6CE-D240DBF69A49 Q36461072-7936AAA7-706B-49AD-9189-021E364044C3 Q37237181-809B204F-BA66-4501-AD2F-3B167E6E3154 Q37530359-529FF816-9FEE-41DB-A5CB-4FC4702CF3EF Q37675437-21007D3E-9695-4F43-858D-F294CB918AC8 Q38215303-D42FB30C-8656-469B-BEC4-5B906E046ACD Q38253128-E5F1EAAA-447F-4B5A-A854-BE9ABA6C85A6 Q38260795-BE197C84-0A7C-49AA-9019-69BB47174130 Q38269612-00F5FA4C-074C-4C29-988C-5BAA9202483F Q38373328-6A876BB8-5D71-446E-8B1F-A4E113008067 Q38676090-83FF881E-1FCB-45A8-A201-3575C4F615AA Q38746156-8389BC15-A309-4ACD-99EE-499540F1C029 Q38925490-1E5D4BEA-1856-4DD1-A383-607B7014C5D7 Q39035495-AB25D16F-8998-4939-B62F-3A72633FC3FC Q39208385-51C2BEDF-B474-433B-88D7-D3ECBA23D638 Q40583165-2B489F1F-5E14-4CCC-9C5B-79E258960C82

P2860

HDAC4 reduction: a novel therapeutic strategy to target cytoplasmic huntingtin and ameliorate neurodegeneration

http://www.wikidata.org/entity/Q27316520

description

2013 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

article scientifique (publié 2013-11)

@fr

articolo scientifico (pubblicato il 2013-11)

@it

artigo científico (publicado na 2013-11)

@pt

artículu científicu espublizáu en 2013

@ast

im November 2013 veröffentlichter wissenschaftlicher Artikel

@de

scientific article (publication date: November 2013)

@en

vedecký článok (publikovaný 2013-11)

@sk

videnskabelig artikel (udgivet 2013-11)

@da

name

HDAC4 reduction: a novel thera ...... d ameliorate neurodegeneration

@ast

HDAC4 reduction: a novel thera ...... d ameliorate neurodegeneration

@en

HDAC4 reduction: a novel thera ...... d ameliorate neurodegeneration

@nl

type

label

HDAC4 reduction: a novel thera ...... d ameliorate neurodegeneration

@ast

HDAC4 reduction: a novel thera ...... d ameliorate neurodegeneration

@en

HDAC4 reduction: a novel thera ...... d ameliorate neurodegeneration

@nl

prefLabel

HDAC4 reduction: a novel thera ...... d ameliorate neurodegeneration

@ast

HDAC4 reduction: a novel thera ...... d ameliorate neurodegeneration

@en

HDAC4 reduction: a novel thera ...... d ameliorate neurodegeneration

@nl

P1433

Q27316520-02D57568-BD76-4FD0-92AB-57A0532131E1

P1476

Q27316520-62882F91-EF00-4B57-8D74-C1333442D6DD

P2093

Q27316520-10B02A8B-8213-4CA0-B061-E02BD61E07C3

Q27316520-377D3416-CF90-4992-9C45-8BB397A24E48

Q27316520-3A358F78-6CFA-4527-B47D-B154DED1515E

Q27316520-579B956E-6466-4DDB-9F5F-7ECDC8EB2DAE

Q27316520-66689D0E-F269-4425-AF48-61FBF129FD95

Q27316520-758BC08F-C07E-49D8-8474-4D5F7CC34591

Q27316520-7C95701C-9C5F-42F3-A28D-DEDA427E91C1

Q27316520-87092144-AE94-4F98-B77A-635586EA06AD

Q27316520-8A83AC82-6262-46BE-A953-E0A3E3A19918

Q27316520-946BBE44-1FB9-4D3C-BB94-0B75A48B44F4

P2860

Q27316520-013FD610-7217-48AC-9D3A-7618E3466E93

Q27316520-07CD7B86-EB47-4F92-8502-C89117C577CA

Q27316520-118BD868-4695-4825-972B-65D07F90B2E5

Q27316520-1893F472-DBD4-4CF2-B1EE-2180554D0053

Q27316520-18D68A33-2B98-4BA6-A741-7A616BBC5A2C

Q27316520-1A89546D-FA98-4EB5-8371-4C102F8A2AF4

Q27316520-1B70BDD5-8007-42A3-B535-9353EEF99237

Q27316520-1F2592F0-7F33-4E47-810B-6AB941040552

Q27316520-2014AAF9-94B6-48C2-A660-3A76A775F479

Q27316520-2469287B-1208-4A56-90DD-98EDBA4E62F3

P304

Q27316520-A49EDA77-214D-4DB8-9EA7-078157111808

P31

Q27316520-71DD9321-B1DE-4F98-BCCF-570E157AEC48

P3181

Q27316520-A334EA4F-6F29-4E9B-A673-74E70B948640

P356

Q27316520-3085F346-B37E-4332-8634-BCDE3C1B352D

P407

Q27316520-6D3BBA79-A89D-4932-8C7C-D7FFBBB6063B

P433

Q27316520-4AE1F655-3AE8-4C18-A3F8-DD1DB6D63FA9

P478

Q27316520-89E61B8B-0913-4141-A084-DCCDB9D21BFD

P50

Q27316520-3C012BAE-3564-4207-BA50-D0666B4D7D98

Q27316520-4337A630-0731-4823-B528-3F1836D96A77

Q27316520-9183A359-1A41-45CB-96AE-064A54A7B0D3

Q27316520-9475AE94-D741-4349-81C3-49B7C3E983B6

Q27316520-973BFC2C-A5C0-481C-9292-1E25C7A78D22

Q27316520-DA9D61D2-EA5F-411C-B286-572AC8D14A73

P577

Q27316520-A2070605-1EE4-48CD-B97A-FD1AF9EF984D

P5875

Q27316520-D825E416-849E-4AF1-ABAB-B15E51426DAF

P698

Q27316520-7798C1A7-F9E1-43E7-AD00-E49B88FE192E

P932

Q27316520-330C1CB2-91EC-4DEC-BA59-EC3D8201BA1E

P3181

P356

JOURNAL.PBIO.1001717

P1433

P1476

HDAC4 reduction: a novel thera ...... d ameliorate neurodegeneration

@en

P2093

Amyaouch Bradaia

http://www.w3.org/2001/XMLSchema#string

Andreas Weiss

http://www.w3.org/2001/XMLSchema#string

Christian Landles

http://www.w3.org/2001/XMLSchema#string

Chrystelle Touller

http://www.w3.org/2001/XMLSchema#string

Donna L Smith

http://www.w3.org/2001/XMLSchema#string

Eric N Olson

http://www.w3.org/2001/XMLSchema#string

Georgina F Osborne

http://www.w3.org/2001/XMLSchema#string

Herman van der Putten

http://www.w3.org/2001/XMLSchema#string

Janette Robertson

http://www.w3.org/2001/XMLSchema#string

Kristian Wadel

http://www.w3.org/2001/XMLSchema#string

P2860

Oligonucleotide therapeutic approaches for Huntington disease

Differential localization of HDAC4 orchestrates muscle differentiation

Class II histone deacetylases: versatile regulators

Structural and functional analysis of the human HDAC4 catalytic domain reveals a regulatory structural zinc-binding domain

Huntingtin and the molecular pathogenesis of Huntington's disease. Fourth in molecular medicine review series

The many roles of histone deacetylases in development and physiology: implications for disease and therapy

Histone deacetylase inhibitors: Potential in cancer therapy

RACE: Remote Analysis Computation for gene Expression data.

SAHA decreases HDAC 2 and 4 levels in vivo and improves molecular phenotypes in the R6/2 mouse model of Huntington's disease

Crystal structure of a conserved N-terminal domain of histone deacetylase 4 reveals functional insights into glutamine-rich domains

P304

e1001717

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

2713395

http://www.w3.org/2001/XMLSchema#string

P356

10.1371/JOURNAL.PBIO.1001717

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

11

http://www.w3.org/2001/XMLSchema#string

P50

Michal Mielcarek

Ruth Luthi-Carter

Tamara Seredenina

P577

2013-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

259155754

http://www.w3.org/2001/XMLSchema#string

P698

24302884

http://www.w3.org/2001/XMLSchema#string

P932

3841096

http://www.w3.org/2001/XMLSchema#string